- A new start for 'Intestinal Research' as an official journal of AOCC
-
Hibi T
- KMID: 2174502
- Intest Res.
- 2016 Jan;14(1):1-1.
- doi: 10.5217/ir.2016.14.1.1
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
-
Yagisawa K, Kobayashi T, Ozaki R, Okabayashi S, Toyonaga T, Miura M, Hayashida M, Saito E, Nakano M, Matsubara H, Hisamatsu T, Hibi T
- KMID: 2504591
- Intest Res.
- 2020 Jul;18(3):343-344.
- doi: 10.5217/ir.2018.00078-c1
-
- CITED
-
- Close
- SHARE
-
- Close
- Ghrelin - A Novel Appetite-stimulating Hormone Which Also Affects Gastrointestinal Functions
-
Suzuki H, Masaoka T, Hibi T
- KMID: 782745
- Korean J Gastroenterol.
- 2006 Aug;48(2):82-88.
Ghrelin, a novel gastrointestinal peptide with 28 amino acids, is secreted from the A-like cells of the gastric fundus. This peptide hormone does not only promote the release of growth... -
- CITED
-
- Close
- SHARE
-
- Close
- Overlap Syndrome of Functional Dyspepsia and Irritable Bowel Syndrome - Are Both Diseases Mutually Exclusive?
-
Suzuki H, Hibi T
- KMID: 2325836
- J Neurogastroenterol Motil.
- 2011 Oct;17(4):360-365.
Among functional gastrointestinal (GI) disorders, functional dyspepsia (FD) and irritable bowel syndrome (IBS) are important to public health around the world and are frequently encountered in general practice. Upper GI... -
- CITED
-
- Close
- SHARE
-
- Close
- What Is the Difference Between Helicobacter pylori-Associated Dyspepsia and Functional Dyspepsia?
-
Suzuki H, Matsuzaki , Hibi T
- KMID: 2326205
- J Neurogastroenterol Motil.
- 2011 Apr;17(2):124-130.
Advances in basic and clinical research have revealed that Helicobacter pylori (H. pylori) infection plays an important role in the development of gastroduodenal dysmotility and hypersensitivity, as also in dyspepsia... -
- CITED
-
- Close
- SHARE
-
- Close
- Ileal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma with a Large-Cell Component That Regressed Spontaneously
-
Makino Y, Suzuki H, Nishizawa , Kameyama K, Hisamatsu , Imaeda H, Mukai M, Hibi T
- KMID: 2167217
- Gut Liver.
- 2010 Mar;4(1):117-121.
Reported herein is a case of mucosa-associated lymphoid tissue (MALT) lymphoma of the terminal ileum with a large-cell component, which regressed spontaneously. To the best of our knowledge, only five... -
- CITED
-
- Close
- SHARE
-
- Close
- Helicobacter pylori and Gastric Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Updated Review of Clinical Outcomes and the Molecular Pathogenesis
-
Suzuki H, Saito Y, Hibi T
- KMID: 1464749
- Gut Liver.
- 2009 Jun;3(2):81-87.
- doi: 10.5009/gnl.2009.3.2.81
In most H. pylori-positive patients, gastric low-grade mucosa-associated lymphoid tissue (MALT) lymphomas regress both endoscopically and histopathologically after H. pylori eradication, but no factors that can be predictive of the... -
- CITED
-
- Close
- SHARE
-
- Close
- Corrigendum: Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies
-
Motoya S, Watanabe M, Kim HJ, Kim YH, Han DS, Yuasa H, Tabira J, Isogawa N, Arai S, Kawaguchi , Hibi T
- KMID: 2417664
- Intest Res.
- 2018 Jul;16(3):499-501.
- doi: 10.5217/ir.2018.16.3.499
The authors regret an error in the reporting of Inflammatory Bowel Disease Questionnaire (IBDQ) patient-reported outcome data in the manuscript. A data extraction error resulted in incorrect IBDQ data being... -
- CITED
-
- Close
- SHARE
-
- Close
- Performing colonoscopy before steroid induction is associated with shorter steroid use in patients with ulcerative colitis
-
Kobayashi T, Udagawa E, Hirose L, Hibi T
- KMID: 2541893
- Intest Res.
- 2023 Apr;21(2):205-215.
- doi: 10.5217/ir.2021.00164
Background/Aims: Risks of long-term steroid use in patients with ulcerative colitis (UC) outweigh the benefits, thus dosing should be tapered once a response is achieved. Colonoscopy is a key technique... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of Solifenacin on Irritable Bowel Syndrome With Diarrhea: Open-label Prospective Pilot Trial
-
Fukushima , Suzuki H, Matsuzaki , Kiyosue A, Hibi T
- KMID: 2325931
- J Neurogastroenterol Motil.
- 2012 Jul;18(3):317-323.
BACKGROUND/AIMS: Solifenacin, a muscarinic type 3 receptor antagonist, is used to treat overactive bladder in adults. The aim of this study is to examine the efficacy of solifenacin on the... -
- CITED
-
- Close
- SHARE
-
- Close
- Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
-
Ogata H, Hagiwara T, Kawaberi T, Kobayashi M, Hibi T
- KMID: 2521605
- Intest Res.
- 2021 Oct;19(4):419-429.
- doi: 10.5217/ir.2020.00033
Background/Aims: Adalimumab has been shown to induce and maintain clinical remission in patients with moderate to severe ulcerative colitis (UC). However, no large-scale population-based studies have been performed in Japan.... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study
-
Ogata H, Ohori A, Nishino H, Mizushima , Hagino A, Hibi T
- KMID: 2382380
- Intest Res.
- 2017 Jul;15(3):358-367.
- doi: 10.5217/ir.2017.15.3.358
BACKGROUND/AIMS: This study compared the efficacy of once-daily administration of multimatrix mesalazine 2.4 g/day with multiple-dose mesalazine for the maintenance of remission. METHODS: In this multicenter, randomized, double-blind study, 203 patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of efficacy of once daily multimatrix mesalazine 2.4 g/day and 4.8 g/day with other 5-aminosalicylic acid preparation in active ulcerative colitis: a randomized, double-blind study
-
Ogata H, Yokoyama T, Mizushima , Hagino A, Hibi T
- KMID: 2417677
- Intest Res.
- 2018 Apr;16(2):255-266.
- doi: 10.5217/ir.2018.16.2.255
BACKGROUND/AIMS: This study compared the efficacy of multimatrix mesalazine 2.4 g/day and 4.8 g/day with controlled-release mesalazine 2.25 g/day. METHODS: In this multicenter, randomized, double-blind study, 251 patients with mildly to... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis: a multicenter, randomized, double-blind, parallel-group study
-
Suzuki Y, Iida M, Ito H, Saida I, Hibi T
- KMID: 2174510
- Intest Res.
- 2016 Jan;14(1):50-59.
- doi: 10.5217/ir.2016.14.1.50
BACKGROUND/AIMS: The therapeutic effect of mesalamine is considered to be dose-dependent; however, no consensus has been reached regarding the optimal doses for individual patients. This study aimed to provide new... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial
-
Hisamatsu , Kunisaki R, Nakamura S, Tsujikawa , Hirai F, Nakase H, Watanabe K, Yokoyama K, Nagahori M, Kanai T, Naganuma M, Michimae H, Andoh A, Yamada A, Yokoyama T, Kamata N, Tanaka S, Suzuki Y, Hibi T, Watanabe M, CERISIER Trial group
- KMID: 2417663
- Intest Res.
- 2018 Jul;16(3):494-498.
- doi: 10.5217/ir.2018.16.3.494
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Is adalimumab safe and effective in patients with intestinal Behcet’s disease in real-world practice?
-
Suzuki Y, Hagiwara T, Kobayashi M, Morita K, Shimamoto T, Hibi T
- KMID: 2518686
- Intest Res.
- 2021 Jul;19(3):301-312.
- doi: 10.5217/ir.2020.00013
Background/Aims: The safety and effectiveness of adalimumab was demonstrated in a phase 3 trial in Japanese patients with intestinal Behçet’s disease. The aim of this study was to evaluate the... -
- CITED
-
- Close
- SHARE
-
- Close
- Steroid-refractory extensive enteritis complicated by ulcerative colitis successfully treated with adalimumab
-
Okabayashi S, Kobayashi , Sujino T, Ozaki R, Umeda S, Toyonaga T, Saito E, Nakano M, Tablante M, Morinaga S, Hibi T
- KMID: 2396405
- Intest Res.
- 2017 Oct;15(4):535-539.
- doi: 10.5217/ir.2017.15.4.535
Extracolonic involvement of the gastrointestinal tract is extremely uncommon in ulcerative colitis (UC) and rarely found in the upper gastrointestinal tract or in postoperative cases since it typically responds to... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study
-
Ogata H, Aoyama N, Mizushima , Hagino A, Hibi T
- KMID: 2382381
- Intest Res.
- 2017 Jul;15(3):368-379.
- doi: 10.5217/ir.2017.15.3.368
BACKGROUND/AIMS: This study assessed the efficacy and safety of high-dose multimatrix mesalazine once-daily (QD) compared to another form of high-dose mesalazine. METHODS: In this multicenter, randomized, double-blind study, 280 patients with... -
- CITED
-
- Close
- SHARE
-
- Close
- 5-Aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis
-
Miyoshi J, Matsuoka K, Yoshida A, Naganuma M, Hisamatsu , Yajima T, Inoue N, Okamoto S, Iwao Y, Ogata H, Ueno F, Hibi T, Kanai T
- KMID: 2434166
- Intest Res.
- 2018 Oct;16(4):635-640.
- doi: 10.5217/ir.2018.00015
Ulcerative colitis (UC) is one of the major clinical phenotypes of inflammatory bowel diseases. Although 5-aminosalicylic acid (5-ASA) is widely used for UC and its efficacy and safety have been... -
- CITED
-
- Close
- SHARE
-
- Close
- Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis
-
Okabayashi S, Kobayashi , Saito E, Toyonaga T, Ozaki R, Sagami S, Nakano M, Tanaka J, Yagisawa K, Kuronuma S, Takeuchi O, Hibi T
- KMID: 2449963
- Intest Res.
- 2019 Apr;17(2):218-226.
- doi: 10.5217/ir.2018.00117
BACKGROUND/AIMS: The pharmacokinetics of tacrolimus (TAC) is known to be largely influenced by single-nucleotide polymorphisms (SNPs) in CYP3A5. Patients starting TAC require careful dose adjustment, owing to the wide range... -
- CITED
-
- Close
- SHARE
-
- Close
